4D Insight

What people say

" ‘The team at 4D have the expertise and understanding to skilfully cover the gap that currently exists between academia and commercialisation. Approachable, informed and able to perform swift analysis of problems and potential solutions relevant to this "

Peter J Grant

Translational medicine, biomarkers and personalised medicine

The drug discovery and development process is undergoing radical change.

Regulators, research councils, charities and pharma companies are committing increasing priority and resource to a new type of (‘translational’) study between traditional discovery and development.
Translational medicine seeks to expose drug discovery pipelines to an intense dose of clinical scrutiny based on clinical insight, tissue samples, pharmacogenomics, patient data bio-informatics.
Powerful new biomarkers are being identified which will enable far greater powers of disease prediction and treatment efficacy and toxicology.

This development has potentially major implications:

Demand for new technologies (microprocessing, imaging)
Major new biomarker licensing and product development opportunities
New markets for niche medicines
Ultimately the rise of personalised predictive medicine, and
The growth of major consumer healthcare ‘wellness’ market

In 2005 we carried out a major research project into translational medicine collaborations around the world, and subsequently advised on the $50m biomarker collaboration recently announced by Wyeth (see case study).

‹ Back to list